Evaluation Review

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click Here for More Information

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mariner, W. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mariner, W. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Evaluation Review, Vol. 14, No. 5, 538-564 (1990)
DOI: 10.1177/0193841X9001400506

The Ethical Conduct of Clinical Trials of HIV Vaccines

Wendy K. Mariner

Boston University

Clinical trials of candidate HIV vaccines pose virtually all of the problems possible in vaccine trials. Resolving them consistently with accepted ethical principles is likely to make trials logistically more difficult, longer, and more expensive than usual. Yet few of these problems are unique to HIV vaccines. What is unique are the social risks that research subjects may face. The major obstacles to testing vaccine candidates in human beings are the same ones that have hindered vaccine development-insufficient knowledge about the virus and the human immune response. The necessarily urgent search for a vaccine to prevent HIV infection does not require subjecting people to unnecessary risks. This article outlines key ethical obstacles to identifying candidate vaccines to test, with special attention to clarifying the benefits and risks of testing experimental vaccines in healthy research subjects. Assuming that such obstacles can be overcome, the article examines how ethical principles governing biomedical research may apply to the design and conduct of clinical trials to ensure independent review of proposed research, identify measures of vaccine effectiveness, identify and monitor suitable research subjects, provide adequate counseling, protect confidential information, and assure compensation for injury and access to any successful vaccine.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Eval RevHome page
M. Morris and R. Cohn
Program Evaluators and Ethical Challenges: A National Survey
Eval Rev, December 1, 1993; 17(6): 621 - 642.
[Abstract] [PDF]